Development of anticancer agents targeting the Wnt/β-catenin signaling

Area of Science:

• Molecular Biology
• Oncology
• Drug Discovery

Background:

• The Wnt/β-catenin signaling pathway is vital for embryonic development and maintaining adult tissue homeostasis.
• Dysregulation of Wnt/β-catenin signaling is a common driver in the development and progression of various cancers.

Purpose of the Study:

• To systematically review therapeutic agents developed for Wnt/β-catenin pathway inhibition.
• To provide an overview of the current clinical trial status for these targeted anticancer agents.

Main Methods:

• Systematic literature review of preclinical and clinical studies.
• Analysis of therapeutic strategies targeting the Wnt/β-catenin cascade.
• Compilation of data on the status of ongoing clinical trials.

Main Results:

• Several classes of therapeutic agents targeting the Wnt/β-catenin pathway have been identified.
• These agents demonstrate potential in preclinical cancer models.
• A subset of these agents is currently undergoing clinical evaluation for efficacy and safety.

Conclusions:

• Targeted inhibition of the Wnt/β-catenin pathway represents a promising therapeutic strategy for cancer treatment.
• Further clinical investigation is warranted to establish the efficacy and safety of these agents in diverse cancer types.